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The Role of Omega-3 Polyunsaturated Fatty Acids in Blood Pressure
Regulation and Secondhand Smoke-Induced Vascular Dysfunction
By
Emily A. Wheeler
B.A., Biochemistry, University of Colorado Boulder, 2016
M.S., Biomedical Sciences, University of New Mexico, 2019
ABSTRACT

Omega-3 polyunsaturated fatty acids (n-3 PUFAs) may lower
cardiovascular disease risk by reducing blood pressure (BP). We hypothesized
that fat-1 transgenic mice, which convert n-6 PUFAs to n-3 PUFAs, would have
improved vascular function in BP regulation and following secondhand smoke
(SHS) exposure, compared to wild type (WT) mice.
BP was recorded in mice fed an n-6 PUFA, or standard chow diet. On the
n-6 PUFA diet fat-1 mice had a lower mean arterial pressure and a greater
decrease in diastolic BP when treated with an ACE inhibitor, compared to WT
mice. No differences were observed on the chow diet. Next, fat-1 mice on the n-6
PUFA or chow diet were exposed to SHS. SHS enhanced vasoconstriction on
the n-6 PUFA diet, but not on chow, but did not affect vasorelaxation.
These data suggest n-3 PUFAs have a protective role in basal BP
regulation and SHS-induced vascular dysfunction.
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CHAPTER 1 – INTRODUCTION

1.1. Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) and Cardiovascular
Disease
A. Structure and Dietary Sources of n-3 PUFAs
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are distinguished from
other fatty acids in that they contain more than two cis double bonds beginning at
the third carbon from the omega (methyl) end (Calder and Yaqoob, 2009) (Fig.
1.1).
Eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA,
22:6n-3) are considered long-chain n-3 PUFAs and can be derived from the
shorter chain n-3 PUFA, α-linolenic acid (ALA, 18:3n-3). Animals do not have the
ability to synthesize ALA. As a result, ALA is considered an essential fatty acid.
However, ALA can be further desaturated and elongated to EPA and ultimately
DHA. In humans, these conversion processes are extremely inefficient (Calder
and Yaqoob, 2009). This is due, in part, to competition between ALA and linoleic
acid (LA, 18:2n-6) to be converted to EPA and arachidonic acid (AA, 20:4n-6),
respectively, by a Δ6 desaturase enzyme. In the Western diet, the amount of LA
consumed far exceeds ALA, so conversion of ALA to EPA is limited (Burdge and
Calder, 2006). Therefore, EPA and DHA are almost exclusively taken in through
diet.
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Fig. 1.1. Structure of the short-chain, plant-derived omega-3 polyunsaturated
fatty acid (n-3 PUFA), α-linolenic acid (ALA) and the long-chain, marinederived n-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA). n-3 PUFAs have a cis double bond beginning at the third carbon from
the omega (ω) end.
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ALA is plant-derived and can be found in leafy green vegetables, pea
plants, and a wide variety of seed oils (Williams and Burdge, 2006). In contrast,
EPA and DHA are largely derived from marine sources such as tuna, herring,
mackerel, anchovies, sardines, salmon, krill, and microalgae (Rimm et al, 2018;
Monroig et al., 2013).
The omega-3 index is defined as the erythrocyte content of EPA and DHA
and is represented as a percentage of total fatty acids. The omega-3 index is a
biomarker for n-3 PUFA consumption and is inversely correlated with
cardiovascular health - a low omega-3 index is a cardiovascular disease (CVD)
risk factor (von Schacky, 2014). Using previous epidemiological and prospective
cohort studies examining the association between n-3 PUFAs and CVD risk,
Harris and von Schacky determined that an omega-3 index of ≤4% is of high
CVD risk, 4-8% is of intermediate CVD risk, and ≥8% is cardioprotective (Harris
and von Schacky, 2004).

B. Protective Mechanisms of n-3 PUFAs
i. Effects of n-3 PUFAs on the Bioavailability of Nitric Oxide
Nitric oxide (NO) is potent signaling molecule produced in vascular
endothelial cells that, when present, relaxes vascular smooth muscle cells,
resulting in arterial and venous vasodilation. NO in vascular endothelial cells is
produced as a product of the conversion of L-arginine to L-citrulline by
endothelial nitric oxide synthase (eNOS) upon various stimuli, including shear
stress and muscarinic and bradykinin receptor activation. Once produced, NO
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diffuses across the cell membranes of vascular smooth muscle cells, in part,
through aquaporin-1, and stimulates vasodilation via activation of soluble
guanylyl cyclase (sGC) (Frei et al., 2009; Herrera and Garvin, 2007).
A number of studies have suggested that n-3 PUFAs, specifically EPA and
DHA, increase NO-dependent vasodilation. Such alterations in NO-dependent
vasodilation may be mediated by increases in the expression of two endothelial
proteins, heat shock protein 90 (Hsp90) and Akt kinase, which are important
participants in the post-transcriptional activation of eNOS (Takahasi and
Mendelsohn, 2003). A study on human coronary artery endothelial cells
(HCAECs) treated with DHA for 7 days demonstrated an increased activation of
Akt kinase (increased phospho-Akt expression) at doses of 5 nM and 50 nM and
an increased expression of Hsp90 at doses of 50 nM and 1 µM. Additionally,
basal cGMP, a product of sGC-dependent vasodilation, was increased in
HCAECs treated with 5 nM DHA (Stebbins et al., 2008).
In unstimulated endothelial cells, eNOS is located within membrane
microdomains known as caveolae. Here, eNOS associates with caveolin, a
scaffolding protein. Various stimuli promote the binding of eNOS to calmodulin
(CaM) and a subsequent dissociation of eNOS from caveolin and the membrane,
resulting in activation of eNOS. Another study on bovine endothelial cells in situ
revealed that treatment of cells with 30 and 60 μM EPA significantly stimulated
the production of NO. In addition, in human umbilical vein endothelial cells
(HUVECs) treated with 30 μM EPA for 15 minutes, eNOS, to a large degree,
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translocated from the plasma membrane to the cytosol, suggesting an activation
of eNOS activity (Omura et al., 2001).
Animal studies have echoed the results seen in cell culture studies that n3 PUFA treatment increases NO-dependent vasodilation. For example, ex vivo
treatment of isolated pulmonary arteries from sheep with 30 µM EPA resulted in
a large degree of vasodilation, which was prevented with L-NG-nitroarginine
methyl ester (L-NAME, NOS inhibitor) treatment or denuding of the endothelium,
suggesting increased NOS-derived synthesis of NO (Singh et al., 2010).
Similarly, EPA treatment improved acetylcholine (ACh)-induced vasodilation in
aortic rings from Apo-E knockout mice, which was attenuated with genetic and/or
pharmacologic inhibition of 5’-AMP-activated protein kinase and eNOS (Wu et
al., 2012). Furthermore, aortic rings from rats fed a menhaden (fish) oil diet
containing EPA and DHA showed no differences in PE constriction compared to
rings of control rats fed a corn oil diet. However, when aortic rings were treated
with Nω-Nitro-L-arginine (L-NNA, NOS inhibitor) in combination with PE, the fish
oil diet resulted in a greater increase in the degree of constriction compared to
rings from control rats fed a corn oil diet, indicating a higher basal NO level in fish
oil-fed rats. Aortic rings from fish oil-fed rats also relaxed to a greater degree in
response to ACh stimulation than did rings from corn oil-fed rats (López et al.,
2001). In another study by the same group, it was revealed that fish oil
supplementation increases both eNOS mRNA and protein expression as well as
production of citrulline, NO, and cGMP (López et al., 2004).
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Other studies have proposed that n-3 PUFAs are protective by reducing
NO scavenging caused by oxidative stress such as occurs with exposure to
cigarette smoke or environmental air pollution, or with cardiovascular diseases,
such as hypertension and diabetes (Zuo et al., 2014; Lodovici and Bigagli, 2011;
Grossman, 2008). These conditions alter the counterbalance between
antioxidants and free radical species such that reactive oxygen and/or nitrogen
species (ROS and RNS) concentrations are significantly increased. Free radicals
can react with NO, thus reducing the bioavailability of NO. It has been shown that
100 μM EPA and 50 μM DHA treatment prevented doxorubucin-induced
increases in ROS in H9C2 (cardiomyocyte) cells (Hsu et al., 2014). Similarly, n-3
PUFA treatment reduced ROS in HUVECs treated with 50 μg/mL fine particles
(PM2.5) (Bo et al., 2016). Taken together, these studies suggest that EPA and/or
DHA treatment improve endothelial function through, in part, reduced scavenging
of NO.

ii. Epoxide Metabolites of n-3 PUFAs as Vasodilators
Arachidonic acid (AA), an n-6 PUFA, is readily metabolized by cytochrome
P450 epoxygenases, specifically CYP2C and 2J, to epoxide metabolites known
as epoxyeicosatrienoic acids (EETs). EETs stimulate vasodilation and are
hypothesized to be endothelium-derived hyperpolarizing factors (EDHF). The
P450 metabolism of long-chain n-3 PUFAs also produces epoxides known as
epoxyeicosatetraenoic acids (EEQs; EPA-derived) and epoxydocosapentaenoic
acid (EDPs; DHA-derived). EEQs and EDPs are also vasodilators and may be
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even more potent than EETs. For instance, ex vivo administration of EPA-derived
epoxides to canine and porcine coronary microvessels resulted in a similar or
greater degree of vasodilation and stimulation of calcium-activated potassium
(BKCa) channels as compared to administration of AA-derived epoxides (Xhang
et al., 2001). EETs, EEQs, and EDPs can be further metabolized by soluble
epoxide hydrolase (sEH) to diols, which have considerably lower bioactivity.
There is some evidence to suggest that EEQs and EDPs are efficacious in
lowering systolic blood pressure (SBP) in mouse models of angiotensin II (Ang
II)-dependent hypertension. Mice infused with Ang II and concurrently treated
with a n-3 PUFA-rich diet and an sEH inhibitor demonstrated decreases in SBP
as compared to Ang II-infused mice fed a corn oil diet (Ulu et al., 2013). In a
follow-up study, the efficacy of 19,20-EDP to lower SBP was assessed in relation
to that of 14,15-EET, an epoxide metabolite of AA. In combination with a sEH
inhibitor, treatment of mice with 19,20-EDP reduced blood pressure by a greater
extent than did 14,15-EET (Ulu et al., 2014).
The mechanism through which epoxide metabolites of long-chain n-3
PUFAs act as vasodilators has not been fully elucidated. It has been proposed
that EDPs and EEQs potently activate large-conductance calcium-activated
potassium (BKCa) channels located within the cell membranes of vascular smooth
muscle cells, causing hyperpolarization of the cell membrane and inactivation of
voltage-dependent Ca2+ channels, thereby inducing relaxation (Ye et al., 2001;
Morin et al., 2008; Ledoux et al., 2006). It has been reported that the BKα
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channel subunit specifically is responsible for the vasodilatory effects of n-3
PUFA epoxide metabolites (Hercule et al., 2007).

iii. Keto-Metabolites of n-3 PUFAs as Antioxidants
Another pathway of n-3 PUFA metabolism is a two-step process involving
cyclooxygenase-II (COX-2) and cellular dehydrogenases within activated
macrophages, generating α,β-unsaturated keto-derivatives (Cipollina, 2015;
Groeger et al., 2010). These electrophilic derivatives adduct nucleophilic protein
residues - the electron-poor β-carbon of the electrophile accepts a pair of
electrons from the electron-rich nucleophile (Cipollina, 2015). Treatment with n-3
PUFAs in healthy adults has been shown to increase the formation of α,βunsaturated keto-derivatives such as 7-oxo-DHA and 5-oxo-EPA without
modulating AA metabolites (Cipollina et al., 2014b). A number of studies suggest
that the antioxidant interactions between n-3 PUFA electrophilic oxo-derivatives
and nucleophiles mediate the cardiovascular protective effects seen n-3 PUFA
treatment.
One mechanism through which keto-metabolites of n-3 PUFAs are
protective is by serving as an antioxidant in conditions of oxidative stress. α,βunsaturated keto-derivatives activate the cytoprotective and antioxidant nuclear
factor erythroid 2-related factor 2 (Nrf2) pathway. 17-oxo-DHA, an oxo-derivative
of DHA, has been shown to induce Nrf2, thereby leading to the transcriptional
activation of cytoprotective enzymes such as heme oxygenase 1 (HMOX1) and
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NAD(P)H quinone dehydrogenase 1 (NQO1) as well as increased production of
glutathione (Cipollina et al., 2014a).
Another potential mechanism through which n-3 PUFA α,β-unsaturated
keto-derivatives may be protective is by suppressing inflammation. For instance,
treatment of peripheral blood mononuclear cells with 17-oxo-DHA reduced both
the transcriptional activation and release of IL-1β and TNFα; these cytokines play
a significant role in the initiation and persistence of inflammation (Cipollina et al.,
2016). Secondly, α,β-unsaturated keto-derivatives serve as inhibitors of the proinflammatory nuclear factor-kappa B (NF-κB) pathway, thus leading to reduced
inflammation. Electrophilic n-3 PUFA oxo-derivatives suppress p65, leading to an
inability of the NF-κB/p65/p50 complex to bind DNA to activate transcription of
inflammatory mediators (Cipollina 2015). Furthermore, α,β-unsaturated ketoderivatives of n-3 PUFAs serve as partial agonists in the peroxisome proliferatoractivated receptor γ (PPARγ) pathway, which decreases the inflammatory
response, especially within vascular endothelial cells (Cipollina et al., 2015;
Hamblin et al., 2009).

iv. n-3 PUFAs and the Renin-Angiotensin System
The renin-angiotensin system (RAS) is a major contributor to basal blood
pressure regulation and its ultimate product is Ang II, a vasoconstrictor. Recently,
evidence has emerged, which suggests that n-3 PUFAs may be cardioprotective
by decreasing the activation of the RAS pathway. In a randomized controlled trial
of 126 hypertensive individuals, a 2 g/day dose of EPA and DHA over 90 days
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significantly decreased SBP compared to individuals given corn oil. This
reduction in SBP was accompanied by significantly lower plasma concentrations
of Ang II compared to those treated with corn oil (Yang et al., 2019). This data
suggests that n-3 PUFAs may be protective by inhibiting the formation of Ang II,
thereby preventing Ang II-dependent vasoconstriction.

C. Effects of n-3 PUFAs on Blood Pressure
Hypertension is one of the most common heath conditions worldwide and
often precedes many cardiovascular diseases, including ischemic heart disease,
stroke, and premature death (Kearney et al., 2005; Kung et al., 2015). It has long
been postulated that n-3 PUFAs may have a hypotensive effect due to their
vasodilatory, oxidative stress reducing, and antioxidant potential.
Evidence suggests that n-3 PUFAs reduce blood pressure in both
hypertensive and normotensive individuals. For example, a meta-analysis of 17
randomized controlled trials regarding the effects of fish oil supplementation on
blood pressure found significant reductions in both systolic and diastolic blood
pressure (DBP) in hypertensive individuals when placed on an n-3 PUFA
intervention. In addition, there were non-significant reductions in systolic and
DBP in normotensive individuals when placed on the same n-3 PUFA
interventions (Campbell et al., 2012). Another meta-analysis examining fish
consumption found that circulating levels of long-chain n-3 PUFA, which are
highly correlated with increased consumption of EPA and DHA, were significantly
associated with a decreased incidence of elevated blood pressure (Yang et al.,
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2016). Furthermore, a recent cross-sectional study of young, normotensive
adults reported a linear inverse association of n-3 PUFA consumption with
systolic and DBP. Individuals in the highest omega-3 index quartile had systolic
and DBPs that were 4 and 2 mmHg lower, respectively, as compared to
individuals in the lowest quartile (Filipovic et al., 2018).
A limited number of animal studies have yielded some mechanistic
details regarding the potential hypotensive effects of n-3 PUFAs. In a rat model
of Ang II-dependent hypertension (Ren-2 rat), consumption of an n-3 PUFAenriched diet significantly reduced SBP, indicating that n-3 PUFAs and/or their
metabolites may protect against Ang II-mediated hypertension (Jayasooriya et
al., 2007). Secondly, intravenous (IV) administration of DHA to wild type mice
reduced arterial blood pressure; in contrast, IV administration of DHA to Slo1
(pore-forming subunit of large-conductance Ca2+ - and voltage-activated K+ (Slo1
BK) channels) knockout mice did not alter blood pressure. This suggests that n-3
PUFAs may reduce blood pressure by activating the pore-forming unit of BK
channels, thus leading to hyperpolarization and vasodilation (Hoshi et al., 2013).
In another model, spontaneously hypertensive rats (SHRs) and
normotensive Wistar Kyoto rats were fed a PUFA-enriched diet containing EPA,
DHA, and γ-linolenic acid (18:3n-6) for 10 weeks. This diet was associated with a
significant drop in blood pressure and an increase in red blood cell total
antioxidant status in SHRs, but not the Wistar Kyoto controls (Frenoux et al.,
2000). Similarly, SHRs fed a krill oil diet had a small, but significant reduction in
SBP that was not seen in normotensive Sprague Dawley rats. The blood
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pressure decrease in SHRs was accompanied by an increase in total serum
NOS activity (Zhou et al., 2017). These animal studies suggest that n-3 PUFAs
prevent hypertension by stimulating vasodilation, increasing antioxidant status,
and increasing NO.

1.2. Secondhand Cigarette Smoke
A. Cigarette Smoke Composition
Tobacco cigarette smoke is a complex mixture of at least 5,000 chemicals
consisting of droplets, particles, and gases (Talhout et al., 2011; Streibel et al.,
2013). Upward of 100 of these chemicals are harmful or potentially harmful
constituents (HPHCs) and many are mutagenic and/or carcinogenic (Margham et
al., 2016). Most notably, cigarette smoke contains toxic compounds such as
polycyclic aromatic hydrocarbons (PAHs), nicotine, tobacco-specific nitrosamines
(TSNAs), aromatic amines, acetaldehyde, formaldehyde, benzene, and various
toxic metals (US Department of Health and Human Services, 2006).
PAHs are generated from the incomplete combustion of organic material
and are a prominent component of cigarette smoke. Cigarette smoke contains
more than 500 PAHs; amongst these, benzo(a)pyrene being is recognized as the
most potent procarcinogenic PAH (Vu et al., 2015). The toxic and carcinogenic
effects of PAH exposure are mediated through activation of the aryl hydrocarbon
receptor (AhR), a cytosolic ligand-activated transcription factor. In its unbound
state, the AhR is complexed with a heat shock protein 90 dimer and AhR
interacting protein (AIP). When present, PAHs diffuse across the cellular
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membrane and bind the AhR, thereby causing a conformational change allowing
the ligand-bound complex to be translocated into the nucleus. After dissociating
from chaperone proteins, the AhR-ligand complex forms a heterodimer with the
AhR nuclear translocator (ARNT), thus allowing the AhR to directly interact with
dioxin-response elements (DREs) contained within DNA. Such interactions
induce the transcription of several genes, including phase I metabolic enzymes
cytochrome P450 (CYP) 1A1 and 1B1 (Cyp1a1 and Cyp1b1). These enzymes
bioactivate PAHs such as benzo(a)pyrene to more reactive compounds that form
adducts within DNA, resulting in mutagenesis and possibly carcinogenesis
(Moorthy et al., 2015).

B. Mainstream versus Sidestream Smoke
When a cigarette is ignited, two chemically distinct tobacco smokes are
generated. Mainstream smoke refers to the smoke that is inhaled and
subsequently exhaled by a smoker, while sidestream smoke refers to the smoke
originating from the burning end of a cigarette. Secondhand smoke (SHS), also
referred to as environmental tobacco smoke (ETS), is a combination of
approximately 85 percent sidestream smoke and 15 percent exhaled mainstream
smoke (US Department of Health and Human Services, 2006).
Qualitatively, mainstream and sidestream smoke share many similarities;
however, their constituents differ in terms of quantity, thus resulting in different
toxicological profiles (US Department of Health and Human Services, 2006;
Streibel et al., 2013). The vast majority of cigarette smoke components are
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present at a higher concentration in sidestream smoke than mainstream smoke,
especially PAHs (Streibel et al., 2013). This is namely due to the fact that
sidestream smoke is generated at lower temperatures than is mainstream
smoke, which results in an incomplete combustion and a production of larger
amounts of PAHs relative to mainstream smoke . Additionally, sidestream smoke
becomes significantly diluted when exposed to room air, which often results in
changes in the chemical and physical properties of the smoke (Streibel et al.,
2013). Lastly, sidestream smoke is unfiltered, while mainstream smoke typically
is filtered, thereby altering the composition of the smoke. All of these factors
contribute to differences in both the concentrations and types of combustion
products present within the smoke.
It has been reported that, at equal doses, sidestream smoke/SHS is more
toxic than mainstream smoke. Based upon a series of unpublished studies
performed on rats by the Philip Morris Tobacco Company in the 1980s,
sidestream smoke was found to be four times more lethal than mainstream
smoke per gram total particulate matter (Schick and Glantz, 2005).

1.3. Cardiovascular Disease in Passive Smokers
A. Health Impacts of Exposure to Secondhand Tobacco Smoke
Exposure to SHS is one of the most substantial causes of indoor air
pollution worldwide with up to 40 percent of children, 35 percent of women, and
33 percent of men exposed on a regular basis (Öberg et al., 2011). This
ultimately leads to an estimated 603,000 deaths worldwide (in the year 2004)
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attributable to SHS exposure (Öberg et al., 2011). A majority of these deaths
occur in third world and developing countries where there is still a large
population of active smokers and/or few to no indoor smoking regulations (Stone
and Zhou, 2016).
Exposure to SHS increases the risk of developing cardiovascular disease
(CVD) by as much as 30 percent (US Department of Health and Human
Services, 2006). CVD encompasses a large family of diseases of the
cardiovascular system, including atherosclerosis, ischemic heart disease,
coronary heart disease, peripheral vascular disease, hypertension, myocardial
infarction, stroke, aortic aneurysm, and others (GBD 2013 Mortality and Causes
of Death Collaborators, 2013; World Health Organization).
There are several mechanisms through which exposure to SHS negatively
impacts the vasculature. SHS impairs endothelial dysfunction, promotes a prothrombotic environment in the vasculature, causes oxidative stress, and reduces
heart rate variability (Celermajer et al., 1996; Otsuka et al., 2001; Kato et al.,
2006; Pope et al., 2001). All of these manifestations of SHS exposure contribute
to an increased CVD risk.

B. Mechanisms of Secondhand Smoke – Induced Vascular Disease
i. Endothelial Dysfunction
Endothelial dysfunction precedes clinical CVD and is characterized by
impaired endothelium-dependent vasodilation resulting, in part, from a reduced
bioavailability of NO. In dysfunctional endothelial cells, loss of NO can result from
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decreased production and/or increased scavenging by reactive free radicals
(Zanetti et al., 2015). Mechanisms involved in reduced production of NO include
uncoupling of eNOS, posttranslational modifications to eNOS, inhibition of eNOS,
and downregulation of eNOS (Förstermann and Münzel, 2006; Karbach et al.,
2014). Increased scavenging largely occurs in conditions of oxidative stress in
which there is an abundance of ROS and RNS.
A vast number of studies have reported that exposure to SHS causes
endothelial dysfunction. Passive smokers have impaired flow-mediated dilation
(FMD) of the brachial artery as compared to those not exposed to SHS,
indicating the presence of endothelial dysfunction in passive smokers
(Celermajer et al., 1996). Similarly, nonsmokers acutely exposed to SHS
experience a significant reduction in coronary flow velocity nearly equal to the
levels seen in active smokers (Otsuka et al., 2001). Additionally, using
ultrasound, the diameter of epicardial coronary artery of female nonsmokers,
passive smokers, and active smokers was monitored after administration of ACh.
The arteries of passive and active smokers constricted, while the arteries of
nonsmokers dilated (Sumida et al., 1998). Both of these studies suggest a similar
degree of endothelial dysfunction in passive and active smokers.
Endothelial dysfunction is an important contributing factor to the
development and progression of atherosclerosis. Normal, healthy endothelial
cells, largely through the production of NO, promote vasodilation and inhibit the
formation of atherosclerosis and thrombosis. However, dysfunctional endothelial
cells promote vasoconstriction and support a pro-inflammatory and pro-
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thrombotic environment (US Department of Health and Human Services, 2006).
In conditions of endothelial dysfunction, endothelial cells lose their nonthrombogenic ability and platelets begin to adhere all the while releasing
chemoattractants and mitogens, thereby encouraging proliferation of vascular
smooth muscle cells (Ross, 1993). Atherosclerosis ultimately perpetuates many
other cardiovascular diseases.

ii. Oxidative Stress
Oxidative stress is an overarching theme in the development of SHSinduced CVD. Oxidative stress refers to an imbalance between free radicals and
antioxidant defense systems that leads to increased accumulation of ROS and
RNS. Free radicals such as superoxide anion (O2·-), nitric oxide (NO·), and
hydroxyl radical (H·), and reactive compounds such as peroxynitrite (ONOO-) are
produced during normal biochemical processes such as aerobic respiration,
oxidation of catecholamines, and activation of electrons in the AA cascade
(Betteridge, 2000). However, at increased concentrations of ROS and RNS, cell
and tissue damage results, which negatively affects the vasculature (Betteridge,
2000).
Importantly in CVD, under oxidative stress, NO can react with superoxide
to form peroxynitrite (US Department of Health and Human Services, 2006). Not
only does this process reduce NO bioavailability, but it also creates a highly toxic
reactive compound. Uncoupling of eNOS, lipid peroxidation, protein peroxidation
and nitration, and inactivation of various enzymes all promote formation of free
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radicals and the perpetuation of oxidative stress (Förstermann and Münzel, 2006;
Novo and Parola, 2008).

1.4. Limitations of Smoke-Free Legislation
Despite popular belief, designated smoking areas do not constitute an
adequate means of preventing SHS exposure since ventilation systems within
buildings and environmental conditions do not allow smoke to be contained
(Hammond, 2002; Yamoto et al., 2013). However, the implementation of smokefree regulations at bars, casinos, restaurants, workplaces, and other public
spaces is an effective means of reducing exposure to SHS. Amongst those
benefiting significantly from smoke-free legislation are children and pregnant
women. In these populations, smoke-free legislation has been associated with
fewer perinatal deaths, preterm births, and hospital visits for respiratory tract
infections/asthma in children (Faber et al., 2016). Recent studies also suggest
that smoke-free legislation may encourage smokers to quit and may discourage
teenagers from becoming smokers (Katikireddi et al., 2016).
Despite its reported successes, more than 80 percent of the world’s
population remains unprotected by smoke-free legislation (WHO Report on the
Global Tobacco Epidemic, 2015). Additionally, smoke-free legislation does not
protect from SHS exposure in private places such as in vehicles and/or at home.
An analysis of the 2016 National Youth Tobacco Survey of U.S. 6th to 12th
graders suggested that, among the 20,675 participants, 21.4% are exposed to
SHS in vehicles and 21.7% are exposed at home (Agaku et al., 2019). As a
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result, smoking cessation is the ultimate goal and programs have been
established by numerous organizations to promote cessation. However, there
remain many individuals that cannot or choose not to quit and as many as 58
million individuals continue to be exposed to SHS. As a consequence, it is
necessary to develop alternative strategies to counter the cardiovascular
morbidity that is brought about by exposure to SHS.

1.5. Rationale for Research
A. Aims and Hypotheses
The benefit and efficacy of n-3 PUFAs in reducing blood pressure,
especially in normotensive individuals, has been heavily debated and there is a
lack of preclinical animal studies that have investigated the relationship between
n-3 PUFAs and blood pressure regulation. Therefore, we aimed to investigate the
role of n-3 PUFAs in the blood pressure regulation of fat-1 transgenic mice and
their wild type (WT) littermates. The fat-1 transgenic mouse contains a fatty acid
desaturase enzyme from Caenorhabditis elegans that allows for the efficient
conversion of n-6 PUFAs to n-3 PUFAs (Kang et al., 2004). Since fat-1 mice
make their own n-3 PUFAs, they do not require supplementation through diet.
We hypothesized that fat-1 mice would have lower blood pressure as a result of
decreased contribution of Ang II to blood pressure regulation, compared to WT
mice on the same diet.
Epidemiological and animal studies have suggested that treatment with n-3
PUFAs reduces CVD risk. In contrast, exposure to SHS increases CVD risk by
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up to 30 percent (US Department of Health and Human Services, 2006). This
raises the question of whether treatment with n-3 PUFAs could counteract the
vascular damage caused by exposure to SHS. We aimed to determine the
effects of SHS exposure on the vascular function on fat-1 mice fed an n-6 PUFA
diet or a standard chow diet with the hypothesis that n-3 PUFAs would protect
against SHS-induced endothelial dysfunction and oxidative stress by preserving
NO bioavailability.
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CHAPTER 2 – METHODS
2.1. The Role of Omega-3 Polyunsaturated Fatty Acids in Blood Pressure
Regulation
A. Chemicals
Chemicals for physiological saline solution (PSS: NaCl, KCl, KH2PO4,
MgSO4, NaHCO3, dextrose, CaNa2EDTA, and CaCl2,), phenylephrine (PE), and
acetylcholine (ACh) were purchased from Sigma-Aldrich (St. Louis, MO).
Captopril was purchased from Fisher Scientific (Pittsburgh, PA).

B. Animals and Diet
Male fat-1 transgenic mice and their WT littermates (hereafter referred to
as WT) were placed on an n-6 PUFA-enriched diet at seven weeks of age
(TD.110517, 15% safflower oil, Teklad Diets, Envigo, Indianapolis, IN) (Table
2.1). Mice were maintained on the n-6 PUFA-enriched diet for a total of eight
weeks at which point mice were switched to a standard chow diet (2920X Rodent
Diet, Teklad Diets, Envigo, Indianapolis, IN) for an additional four weeks. All
animal protocols were approved by the University of New Mexico Animal Care
and Use Committee.

21

TABLE 2.1. Fatty acid content of n-6 PUFA and standard chow diets.
% of Total Fatty Acids
Total
Fatty
Acids (%
of Diet)

Calories
From
Fat (%)

Saturated

MUFA

n-6
PUFA

n-3
PUFA

n-6 PUFA

15.0a

32.6

8.9

13.1

78.0

0.0

Standard
Chow

6.5

16.0

14.5

20.0

47.3

5.5

PUFAc
b

aValues estimated from data sheets provided by the manufacturer.
bMUFA: monounsaturated fatty acid.
cPUFA: polyunsaturated fatty acid.

C. Aortic Vasoreactivity
Mice were anesthetized with an intraperitoneal (i.p.) injection
ketamine/xylazine (80/4 mg/kg) and were subsequently euthanized by
exsanguination. The thoracic aorta was excised and placed in ice-cold PSS
(130 mM NaCl, 4.7 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 14.9 mM
NaHCO3, 5.5 mM dextrose, 26 mM CaNa2EDTA, 1.8 mM CaCl2, pH 7.4). The
aorta was cleaned of perivascular adipose tissue (PVAT), sectioned into two 3
mm rings, and mounted to a wire myograph (Radnoti Glass Technologies,
Monrovia, CA) attached to a force transducer (Grass Technologies, West
Warwick, RI). Aortic rings were contained in 37°C PSS bubbled with 20% O 2, 5%
CO2, and balance N2. Aortic rings were allowed to equilibrate for 80 minutes,
gradually increasing to a baseline tension of 1500 mg. The rings were then
constricted with 100 mM KCl in order to confirm viability. To ensure an intact
endothelium, aortic rings were constricted with a bolus dose of PE (10 -5 M) and
subsequently dilated with ACh (10-5 M). Dose-dependent constriction to PE (10-
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7.5

– 10-5.0 M) was assessed and was immediately followed by a dose-dependent

relaxation to ACh (10-8.2 – 10-5.1 M).

D. Measurement of Blood Pressure, Heart Rate, and Activity
At 10 weeks of age, male WT and fat-1 mice were surgically implanted
with PA-C10 radiotelemeters (Data Sciences International, St. Paul, MN) to
monitor mean arterial pressure (MAP), systolic blood pressure (SBP), diastolic
blood pressure (DBP), heart rate (HR), and activity. MAP was calculated as
1

𝑀𝐴𝑃 ≅ 𝐷𝐵𝑃 + 3 (𝑆𝐵𝑃 − 𝐷𝐵𝑃) . Mice were allowed to recover for 3-4 weeks
before baseline recordings began. Blood pressure was recorded for a 10-second
period once every 15 minutes for a total of 6 days (3 days of baseline and 3 days
of captopril treatment) while mice were fed an n-6 PUFA-enriched diet. This
procedure was repeated when mice were switched to a standard chow diet.

E. Captopril Treatment
For each diet, after 3 days of baseline recording, WT and fat-1 mice were
administered captopril, an angiotensin-converting enzyme (ACE) inhibitor, in
drinking water at a dose of 4 mg/kg/day for a 3-day duration. Before sacrifice,
mice underwent a 3-day washout period.

F. Body and Tissue Weights
Body weights were determined twice weekly beginning at the date of
surgery and continuing until mice were sacrificed. Mice were anesthetized with
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an intraperitoneal (i.p.) injection of ketamine/xylazine (80/4 mg/kg) and then
euthanized by exsanguination. Whole blood was collected by cardiac puncture
and serum was obtained by centrifugation at 3000 g and 4°C for 15 minutes. The
heart was collected and atria were removed to obtain a total heart weight. Kidney
weights were recorded as well. Serum, heart, kidneys, and abdominal/thoracic
aorta were collected, flash frozen, and stored at -80°C for future analyses.

G. Fatty Acid Analysis
Approximately 50 μL of whole blood was collected onto antioxidant-treated
filter paper provided by OmegaQuant (Sioux Falls, SD) from mice on a standard
chow diet, mice on an n-6 PUFA-enriched diet for eight weeks, and mice on an n6 PUFA-enriched diet for eight weeks followed by chow diet for four weeks.
These dried blood spots were sent to OmegaQuant (Sioux Falls, SD) for analysis
of fatty acid content using a gas chromatographic method described previously
(Harris and Polreis, 2016).

H. Gene Expression
Total RNA was isolated from lung, heart, and liver using the RNeasy Mini
Kit (Qiagen, Hilden, Germany). RNA was isolated from adipose tissue using a
combined TRIzol and miRNeasy kit (Qiagen, Hilden, Germany) method (Cirera,
2013). cDNA was generated using an iScript Reverse Transcription Supermix
(BioRad Laboratories, Inc., Hercules, CA). qPCR analysis was performed using
iTaq Universal SYBR Green Supermix (Bio-Rad), cDNA, and forward and
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reverse primers for hypoxanthine-guanine phosphoribosyltransferase (Hprt) or
angiotensinogen (Agt) on the CFX Connect Real-Time PCR Detection System
(Bio-Rad) (Table 2.2).

TABLE 2.2. Real-Time qPCR Primer Sequences
Gene

Forward Primer

Reverse Primer

Hprt
Agt

5' AGGGATTTGAATCAGTTTG
5' TCCTGACTTGGATAGTGAAC

5' TTTACTGGCAACATCAACAG
5' CTATTGAGAACCTCTCCCAC

I. Statistical Analysis
Fatty acid profiles of WT and fat-1 mice on an n-6 PUFA diet and on a
standard chow diet were compared using Two-Way Analysis of Variance
(ANOVA). Body weight, MAP, SBP, DBP, pulse pressure, heart rate, and activity
of WT and fat-1 mice were compared to each other at baseline and during
captopril treatment within each diet using t-test. ΔMAP, ΔSBP, ΔDBP, Δheart rate,
and Δactivity (change from baseline) resulting from captopril treatment as well as
Agt mRNA expression were compared in WT and fat-1 mice using t-test.

2.2. The Role of Omega-3 Polyunsaturated Fatty Acids in Secondhand SmokeInduced Vascular Dysfunction
A. Chemicals and Materials
3R4F research cigarettes were purchased from the University of Kentucky
(Lexington, KY). Chemicals for PSS (NaCl, KCl, KH2PO4, MgSO4, NaHCO3,
dextrose, CaNa2EDTA, and CaCl2,), PE, ACh, and Nω-Nitro-L-arginine (L-NNA)
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were purchased from Sigma-Aldrich (St. Louis, MO). U46619 and S-nitroso-Nacetyl-D,L-penicillamine (SNAP) were purchased from Cayman Chemical (Ann
Arbor, MI).

B. Animals and Diet
Male fat-1 transgenic mice were housed in a temperature-controlled
environment and were fed a standard chow diet (2920X Rodent Diet, Teklad
Diets, Envigo, Indianapolis, IN) until four weeks of age. At four weeks old, half of
the mice were switched to an n-6 PUFA-enriched diet (TD.110517, 15%
safflower oil, Teklad Diets, Envigo, Indianapolis, IN) for a total of eight weeks,
while the other half of the mice remained on the chow diet until the conclusion of
the study (see Table 2.1 on page 21).

C. Exposures to Secondhand Tobacco Smoke
Fat-1 mice were assigned to either air- or a secondhand smoke (SHS)exposed groups according to their diet (four groups: n-6 PUFA/Air, n-6
PUFA/SHS, Chow/Air, Chow/SHS, n = 6-9 per group). Beginning at eight weeks
of age, mice were exposed to the whole-body sidestream smoke of nine
University of Kentucky 3R4F reference cigarettes (9.4 mg tar and 0.73 mg
nicotine per cigarette). This process was repeated five days per week for a total
of four weeks. Sidestream smoke was generated using the SCIREQ inExpose
system (SCIREQ, Montreal, Canada). Mainstream smoke was produced and
immediately evacuated by a two second, 35 mL puff per minute. A bias flow of
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1.2 L/min from the burning end of the cigarette maintained air and sidestream
smoke concentrations within the whole-body exposure chamber. Total particulate
matter (TPM) was measured every two weeks and was maintained at an average
of 115.4 mg/m3. Mice were sacrificed 24 to 72 hours after the conclusion of the
last SHS exposure.

D. Body and Tissue Weights
Body weights were determined twice daily for the eight week duration of
the study. Urine was collected onto a sheet of parafilm upon removing mice from
their cages and stored at -80°C. Mice were anesthetized with an intraperitoneal
(i.p.) injection of ketamine/xylazine (80/4 mg/kg) and were subsequently
euthanized by exsanguination. Whole blood was collected by cardiac puncture
and serum was obtained by centrifugation at 3000 g and 4°C for 15 minutes. The
heart was collected and atria were removed to obtain a total heart weight. The
right ventricle (RV) was dissected away to obtain right ventricle and left ventricle
plus septal weights (LV+S). The LV+S section was divided into two pieces – one
half fixed in 10% neutral buffered formalin and the other flash frozen and stored
at -80°C. Additionally, lung, liver, and kidneys were weighed and these tissues
plus abdominal adipose were flash frozen and stored at -80°C.

E. Fatty Acid Analysis
Approximately 50 μL of whole blood was collected onto antioxidant-treated
filter paper cards supplied by OmegaQuant (Sioux Falls, SD) from mice on a
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standard chow diet, mice on an n-6 PUFA-enriched diet for four weeks, and mice
on an n-6 PUFA-enriched diet for eight weeks. Dried blood spots were sent to
OmegaQuant for analysis of fatty acid content using a gas chromatographic
method described previously (Harris and Polreis, 2016).

F. Aortic Vasoreactivity
After 4 weeks of SHS or air exposure, fat-1 mice were euthanized as
described above. The thoracic aorta was excised and placed in ice-cold PSS
(130 mM NaCl, 4.7 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 14.9 mM
NaHCO3, 5.5 mM dextrose, 26 mM CaNa2EDTA, 1.8 mM CaCl2, pH 7.4). The
aorta was cleaned of perivascular adipose tissue (PVAT), sectioned into two 3
mm rings, and mounted to a wire myograph (Radnoti Glass Technologies,
Monrovia, CA) attached to a force transducer (Grass Technologies, West
Warwick, RI). Aortic rings were contained in 37°C PSS bubbled with 20% O2, 5%
CO2, and balance N2. Aortic rings were allowed to equilibrate for 80 minutes,
gradually increasing to a baseline tension of 1500 mg. The rings were then
constricted with 100 mM KCl in order to confirm viability. To ensure an intact
endothelium, aortic rings were constricted with a bolus dose of PE (10-5 M) and
subsequently dilated with ACh (10-5 M). Afterward, dose-dependent constriction
to either PE (10-7.5 – 10-5.0 M) or U46619 (10-9.0 – 10-8.3 M) was assessed and was
immediately followed by a dose-dependent relaxation to either ACh (10-9.0 – 10-8.3
M) or SNAP (10-9.0 – 10-8.3 M). PE, U46619, and ACh dose responses were
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completed in the absence and presence of L-NNA (10 μM, 30 minute preincubation), a NOS inhibitor.

G. Urinary Cotinine
Urine was collected from mice within 18 hours of the last exposure.
Urinary cotinine, a metabolite of nicotine, was assessed as an index of exposure
to SHS using a cotinine ELISA kit (MyBioSource, Inc., San Diego, CA).

H. Gene Expression
Total RNA was isolated from lung, heart, and liver using the RNeasy Mini
Kit (Qiagen, Hilden, Germany). RNA was isolated from adipose tissue using a
combined TRIzol and miRNeasy kit method (Cirera, 2013). cDNA was generated
using an iScript Reverse Transcription Supermix (BioRad Laboratories, Inc.,
Hercules, CA). qPCR analysis was performed using iTaq Universal SYBR Green
Supermix (Bio-Rad), cDNA, and forward and reverse primers for hypoxanthineguanine phosphoribosyltransferase (Hprt), Cytochrome P450 1A1 (Cyp1a1),
Cytochrome P450 1B1 (Cyp1b1), NADP(H) quinone dehydrogenase 1 (Nqo1), or
heme oxygenase 1 (Hmox1) on the CFX Connect Real-Time PCR Detection
System (Bio-Rad) (Table 2.3).
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TABLE 2.3. Real-Time qPCR Primer Sequences
Gene

Forward Primer

Reverse Primer

Hprt
Cyp1a1
Cyp1b1
Nqo1
Hmox1

5' AGGGATTTGAATCAGTTTG
5' GGAACTAGACACAGTGATTG
5' ACTATTACGGACATCTTCGG
5' CCTTTCCAGAATAAGAAGACC
5' CATGAAGAACTTTCAGAAGGG

5' TTTACTGGCAACATCAACAG
5' TTGGGGATATAGAAGCCATTC
5' ATCTGGTAAAGAGGATGAGC
5' AATGCTGTAAACCAGTTGAG
5' TAGATATGGTACAAGGAAGCC

I. Oxidative Stress Analysis
Total antioxidant capacity was assessed as an index of oxidative stress
using a commercially available kit (Cayman Chemical, Ann Arbor, MI).

J. Histology
The left ventricle of each heart was fixed in 10% neutral buffered formalin
(NBF) and stored at 4°C. Paraffin-embedded sections were stained using
picrosirius red and visualized using light microscopy. The degree of fibrosis
within the cardiac sections was assessed qualitatively.

K. Statistical Analysis
Diet and exposure comparisons of body and tissue weights, fatty acid
profiles, total antioxidant capacity, and gene expression from fat-1 mice were
assessed using Two Way ANOVA. Constriction and relaxation dose response
curves were compared between air- and SHS-exposed fat-1 mice using TwoWay Repeated Measures (RM) ANOVA. Urinary cotinine concentrations and
area under the curve (AUC) was analyzed by t-test.
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CHAPTER 3 – RESULTS – The Role of Omega-3 Polyunsaturated Fatty
Acids in Blood Pressure Regulation

3.1. Body Weight at Baseline Did Not Differ Between WT and Fat-1 Mice on
Either Diet
Body weight at baseline did not differ significantly between WT and fat-1
mice when fed an n-6 PUFA diet or a standard chow diet (Table 3.1). At baseline,
WT mice fed a standard chow diet weighed significantly more than WT mice fed
an n-6 PUFA diet. This effect was not seen in fat-1 mice.

TABLE 3.1. Average body weight of WT and fat-1 mice measured at baseline
when fed an n-6 PUFA diet and a standard chow diet.

n-6 PUFA
Standard Chow

Body Weight at Baseline (g)
Fat-1
WT
a
28.0 ± 0.6
27.1 ± 0.8
32.9 ± 1.0*
39.5 ± 1.7

Average
Age
15 Weeks
20 Weeks

aValues

are expressed as mean ± SE (n=5). Data were analyzed by t-test.
*p<0.05 versus WT mice fed an n-6 PUFA diet.

3.2. Genotype and Diet Significantly Altered Red Blood Cell Fatty Acid
Composition
To determine the effects of genotype and diet on fatty acid composition,
levels of red blood cell fatty acids were assessed. When mice were fed an n-6
PUFA diet, levels of all n-3 PUFAs, including ALA, EPA, DHA, and
docosapentaenoic acid (n-3 DPA), were significantly higher in fat-1 mice
compared to WT mice (Table 3.2). In contrast, levels of the n-6 PUFAs, AA,
docosatetraenoic acid, and docosapentaenoic acid (n-6 DPA), were significantly
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lower in fat-1 mice compared to WT when fed an n-6 PUFA diet. When mice
were fed a standard chow diet, levels of EPA, n-3 DPA, and DHA as well as
omega-3 index (red blood cell percentage of EPA and DHA) were significantly
higher in fat-1 mice compared to WT. Levels of the n-6 PUFAs, LA, AA,
docosatetraenoic acid, and n-6 DPA, were significantly lower in fat-1 mice
relative to WT.
When comparing between diets, both WT and fat-1 mice fed a standard
chow diet had significantly higher levels of all n-3 PUFAs and significantly lower
levels of all n-6 PUFAs, except eicosatrienoic acid, compared to WT and fat-1
mice fed the n-6 PUFA diet.
In addition, the omega-3 index was significantly higher in fat-1 mice versus
WT on both diets, and was significantly higher in mice fed the standard chow
diet, compared to the n-6 PUFA diet (Fig. 3.1A). As the omega-3 index
decreased, the n-6 PUFA/n-3 PUFA ratio tended to increase (Fig. 3.1B). WT and
mice fed an n-6 PUFA diet had a significantly higher n-6 PUFA/n-3 PUFA ratio
compared to WT and fat-1 mice fed a standard chow diet. On each diet, WT mice
had a significantly higher n-6 PUFA/n-3 PUFA ratio relative to their fat-1
counterparts.
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TABLE 3.2. Red blood cell fatty acid composition of WT and fat-1 mice fed an n6 PUFA diet for 8 weeks and a standard chow diet for 4 weeks.
n-6 PUFA Diet
Fatty Acid

Standard Chow Diet

WT

Fat-1

WT

Fat-1

C18:3n3
(α-Linolenic, ALA)

0.03 ± 0.01a

0.15 ± 0.01*

0.38 ± 0.03#

0.46 ± 0.07#

C20:5n3
(Eicosapentaenoic, EPA)

0.03 ± 0.01

0.85 ± 0.04*

0.18 ± 0.01#

1.14 ± 0.05 *#

C22:5n3
(Docosapentaenoic,
n-3 DPA)

0.08 ± 0.01

1.06 ± 0.04*

0.45 ± 0.02#

1.39 ± 0.03*#

C22:6n3
(Docosahexaenoic, DHA)

1.08 ± 0.04

5.27 ± 0.13*

4.12 ± 0.05#

6.54 ± 0.19*#

Omega-3 Index
(EPA+DHA)

1.12 ± 0.05

6.11 ± 0.16*

4.31 ± 0.05#

7.68 ± 0.23*#

Σn-3 PUFAs

1.23 ± 0.05

7.42 ± 0.20*

5.14 ± 0.06#

9.53 ± 0.23*#

C18:2n6
(Linoleic)

24.22 ± 0.59

25.02 ± 0.40

20.01 ± 0.54#

22.02 ± 0.89#

C18:3n6
(γ-Linolenic)

0.25 ± 0.02

0.28 ± 0.02

0.17 ± 0.02#

0.19 ± 0.01#

C20:2n6
(Eicosadienoic)

0.44 ± 0.03

0.43 ± 0.02

0.25 ± 0.02#

0.30 ± 0.02#

C20:3n6
(Eicosatrienoic)

1.40 ± 0.05

1.40 ± 0.03

1.44 ± 0.04

1.53 ± 0.08

C20:4n6
(Arachidonic)

19.82 ± 0.41

16.18 ± 0.40*

17.47 ± 0.59#

12.19 ± 0.94*#

C22:4n6
(Docosatetraenoic)

1.78 ± 0.04

0.99 ± 0.02*

1.33 ± 0.03#

0.64 ± 0.03*#

C22:5n6
(Docosapentaenoic,
n-6 DPA)

3.49 ± 0.06

0.92 ± 0.04*

1.54 ± 0.04#

0.43 ± 0.03*#

Σn-6 PUFAs

51.41 ± 0.56

45.21 ± 0.41*

42.21 ± 0.32#

37.30 ± 0.31*#

Σn-6/n-3 PUFA ratio

42.05 ± 1.60

6.13 ± 0.20*

8.21 ± 0.11#

3.92 ± 0.08*

n-3 PUFAs

n-6 PUFAs

aValues

are expressed as mean ± SE (n=5). Data were analyzed by Two-Way ANOVA with
Holm-Sidak post hoc comparisons.
*p<0.01 versus WT mice fed the same diet.
#p<0.01 versus mice of the same genotype fed an n-6 PUFA diet.
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Fig. 3.1. Omega-3 index (A) and n-6 PUFA/n-3 PUFA ratio (B) in WT and fat-1
*P<0.05
WT mice on the
samediet.
diet Data are presented as mean
mice fed an n-6 PUFA
dietversus
or standard
chow
#P<0.05 versus mice of the same genotype fed an n-6 PUFA diet
± SE (n=5) and were analyzed by Two-Way ANOVA with Holm-Sidak post-hoc
comparisons. *p<0.05 versus WT mice on the same diet, #p<0.05 versus mice
of the same genotype fed an n-6 PUFA diet.
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3.3. Aortic Vasoreactivity to Phenylephrine and Acetylcholine Was Not
Affected By Genotype on Either Diet
Dose-dependent constriction and relaxation were performed on isolated
aortic rings using PE and ACh, respectively, in order to assess the contribution of
NO to the regulation of vascular tone. If the contribution of NO to blood pressure
regulation were increased in fat-1 mice, compared to WT, it would be expected
that constriction to PE would be reduced and relaxation to ACh would be
increased. However, aortic responsiveness to PE did not differ between WT and
fat-1 mice on either diet (Fig. 3.2A,B). In addition, relaxation to ACh was not
different between WT and fat-1 mice fed an n-6 PUFA diet (Fig. 3.2C); however,
relaxation to ACh was significantly greater at the two highest doses in fat-1 mice
fed the standard chow diet, compared to WT (Fig. 3.2D). Taken together, these
results suggest a limited role of NO in aortic vasoreactivity.
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Fig. 3.2. Dose-dependent aortic constriction to PE (A,B) and relaxation to ACh
(C,D). Data are presented as mean ± SE (n=7-9) and were analyzed by TwoWay RM ANOVA with Holm-Sidak post-hoc comparisons. *p<0.05 versus WT
mice on the same diet
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3.4. Blood Pressure was Lower in Fat-1 Mice Compared to WT When Fed an n6 PUFA Diet
MAP, SBP, and DBP were measured over the course of two 3-day periods
(3 days baseline followed by 3 days captopril treatment (4 mg/kg/day in drinking
water)) in WT and fat-1 mice first fed an n-6 PUFA diet for 8 weeks and then a
standard chow diet for 4 weeks. When fed an n-6 PUFA diet, MAP was
significantly lower in fat-1 mice at baseline and on captopril, compared to WT
mice (Fig. 3.3A). Further, there was a trend towards a larger decrease in MAP
(ΔMAP) when fat-1 mice were treated with captopril, compared to WT (p=0.09)
(Fig. 3.3B).
SBP was not significantly different between WT and fat-1 mice at baseline
or on captopril, but there was a trend towards a lower SBP in fat-1 mice both at
baseline and on captopril (p=0.10 and p=0.09, respectively) (Fig. 3.3C).
However, the decrease in SBP (ΔSBP) during captopril treatment was not
different between WT and fat-1 mice (Fig. 3.3D). In contrast to SBP, DBP was
significantly lower in fat-1 mice, compared to WT when on captopril (Fig. 3.3C),
and showed a trend towards a lower DBP at baseline (p=0.07), compared to WT
mice (Fig 3.3E). Notably, the decrease in DBP (ΔDBP) during captopril treatment
was significantly greater in fat-1 mice fed an n-6 PUFA, compared to WT mice
fed the same diet (Fig. 3.3F).
When fed a standard chow diet, MAP, SBP, and DBP as well as ΔMAP,
ΔSBP, and ΔDBP did not differ significantly between WT and fat-1 mice at
baseline or on captopril (Fig. 3.4A-F). Further, pulse pressure, the difference
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between SBP and DBP, was not different between WT and fat-1 mice at baseline
or on captopril (Supplementary Fig. 3.6).
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Fig. 3.3. MAP (A), SBP (C), and DBP (E), in WT and fat-1 mice fed an n-6 PUFA
diet at baseline and on captopril (4 mg/kg/day in drinking water on an n-6 PUFA
diet. ΔMAP (B), ΔSBP (D), and ΔDBP (F) resulting from captopril treatment. Data
are presented as mean ± SE (n=5) and were analyzed by t-test.
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Fig. 3.4. MAP (A), SBP (C), and DBP (E), in WT and fat-1 mice fed a standard
chow diet at baseline and on captopril (4 mg/kg/day in drinking water on a
standard chow diet. ΔMAP (B), ΔSBP (D), and ΔDBP (F) resulting from captopril
treatment. Data are presented as mean ± SE (n=5) and were analyzed by t-test.
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3.5. Heart Rate and Activity Were Not Significantly Different Between WT and
Fat-1 Mice on Either Diet
In addition to the measurements of BP, surgically implanted
radiotelemeters also recorded heart rate and activity of WT and fat-1 mice over
two 3-day periods (3 days baseline followed by 3 days captopril treatment).
Regardless of diet, there were no significant differences in heart rate or activity
between WT and fat-1 mice at baseline or on captopril (Supplementary Fig. 3.7AD and 3.8A-D). In addition, there were no significant differences between WT and
fat-1 mice in Δheart rate or Δactivity when treated with captopril.

3.6. Angiotensinogen (Agt) mRNA Expression Was Not Significantly Different
Between WT and Fat-1 Mice Fed an n-6 PUFA Diet
To further examine the role of Ang II in the regulation of blood pressure in
WT and fat-1 mice, Agt mRNA expression, the substrate for the rate-limiting
enzyme in Ang II generation, was measured in abdominal white adipose tissue,
heart, liver, and lung. In adipose, there was a trend towards decreased Agt
expression in fat-1 mice compared to WT (p=0.06) (Fig. 3.4A). However, Agt
mRNA expression did not differ between WT and fat-1 mice fed an n-6 PUFA diet
in heart, liver, or lung (Fig. 3.5B-D). Finally, Agt mRNA expression did not differ
between WT and fat-1 mice fed the standard chow diet (data not shown).
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3.7. Summary
Vascular reactivity to PE and ACh were not different between WT and fat1 mice when fed the n-6 PUFA diet, while ACh showed an increased relaxation in
fat-1 mice on a standard chow diet. When mice were fed the n-6 PUFA diet,
MAP was significantly lower in fat-1 mice, compared to WT. When treated with
captopril, MAP and DBP were reduced and ΔDBP was significantly greater in fat1 mice fed an n-6 PUFA diet, compared to WT mice fed the same diet. However,
no significant differences were seen between WT and fat-1 mice in MAP or SBP.
When mice were fed a standard chow diet, MAP, SBP, and DBP were unaffected
by genotype and diet both at baseline and on captopril treatment. Regardless of
diet, there were no differences in heart rate or activity. There was a trend towards
a decreased Agt mRNA expression in fat-1 mice compared to WT only when
mice were fed an n-6 PUFA diet.
Taken together these data suggest that there may a small but detectable
increase in NO bioavailability to vascular relaxation as the omega-3 index
approaches a level defined as protective in humans (≥ 8%; fat-1 mice on
standard chow diet, 7.7 ± 0.2%). However, this increase in NO is not reflected by
any changes in BP regulation, compared to WT mice with an omega-3 index in
the intermediate risk range (4-8%; WT mice omega-3 index of 4.3 ± 0.2%). In
contrast, however, an omega-3 index in the intermediate risk range observed in
fat-1 mice on an n-6 PUFA diet (6.1 ± 0.2%) results in significantly lower DBP
and increased contribution of Ang II to BP regulation, compared to a very low and
high risk omega-3 index (1.1 ± 0.1%). This suggests that the BP lowering
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benefits of n-3 PUFAs occur at intermediate omega-3 index levels, compared to
very low omega-3 index levels.
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3.8. Supplementary Information
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Supplementary Fig. 3.6. Pulse pressure in WT and fat-1 mice fed an n-6 PUFA
diet (A) or a standard chow diet (B) at baseline and on captopril (4 mg/kg/day
in drinking water). Data are presented as mean ± SE (n=5) and were analyzed
by t-test.
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Supplementary Fig. 3.7. Heart rate (A) and activity (C) in WT and fat-1 mice
fed an n-6 PUFA diet at baseline and on captopril (4 mg/kg/day in drinking
water). ΔHeart rate (B) and Δactivity (D) resulting from captopril treatment. Data
are presented as mean ± SE (n=5) and were analyzed by t-test.
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Supplementary Fig. 3.8. Heart rate (A) and activity (C) in WT and fat-1 mice
fed a standard chow diet at baseline and on captopril (4 mg/kg/day in drinking
water). ΔHeart rate (B) and Δactivity (D) resulting from captopril treatment. Data
are presented as mean ± SE (n=5) and were analyzed by t-test.
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CHAPTER 4 – RESULTS – The Role of Omega-3 Polyunsaturated Fatty
Acids in Secondhand Smoke-Induced Vascular Dysfunction

4.1. Total Particulate Matter
Total particulate matter (TPM) was measured within the whole-body
exposure chamber every other week throughout the course of the study. Over 10
measurements, the average TPM was 115 mg/m3. A representative time course
of TPM is shown in Fig. 4.1.
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Fig. 4.1. TPM in the whole-body exposure chamber measured over a 120minute time course. TPM was maintained at an average of 115 mg/m 3.
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4.2. Urinary Cotinine was Elevated in SHS-Exposed Mice Compared to AirExposed Mice
Urinary cotinine concentrations were determined by ELISA at baseline and
at four weeks post air or SHS exposure as an index of exposure to SHS (Table
4.1). At baseline, cotinine concentrations were not significantly different between
air- and SHS-exposed mice. After 4 weeks of either air or SHS exposure, urinary
cotinine levels were significantly higher in SHS-exposed mice compared to air
exposed mice. The urinary cotinine concentrations seen in SHS-exposed mice
are comparable to urinary cotinine concentrations seen in human nonsmokers
exposed to SHS (Jarvis et al., 1987; Jung et al., 2012).

TABLE 4.1. Urinary cotinine concentrations at baseline and after 4 weeks of air
or SHS exposure.
Urinary Cotinine (ng/mL)a
Baseline

4 Weeks Exposure

Air

0.28 ± 0.03b

0.26 ± 0.03

SHS

0.27 ± 0.03

3.83 ± 0.92*#

aLimit

of detection was 0.1 ng/mL.
are presented as mean ± SE (n=7-9) and were analyzed by t-test.
*p<0.05 versus air-exposed mice at the same time point.
#p<0.05 versus SHS-exposed mice at baseline.
bData
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4.3. Cyp1a1 and Cyp1b1 mRNA Expression
Cyp1a1 and Cyp1b1 mRNA expression was assessed as an index of
exposure to SHS. Adipose tissue, a storage depot for SHS-derived organic
compounds, demonstrated increased Cyp1a1 mRNA expression following SHS
exposure in mice fed the standard chow diet, but not mice fed the n-6 PUFA diet
(Fig. 4.2A). Additionally, both air- and SHS-exposed mice fed the standard chow
diet had a significantly lower Cyp1a1 mRNA expression, compared to mice fed
the n-6 PUFA diet. In contrast, SHS exposure significantly increased Cyp1b1
mRNA expression in adipose of mice fed an n-6 PUFA diet, but not in mice fed a
standard chow diet (Fig. 4.2B). Cyp1a1 and Cyp1b1 mRNA expression in lung
and heart tissue demonstrated no effects of diet or SHS exposure
(Supplementary Fig. 4.10).
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Fig. 4.2. Cyp1a1 (A) and Cyp1b1 (B) mRNA expression in abdominal adipose
*p<0.05 versus air-exposed
same
diet. diet or standard chow
tissue from air- and SHS-exposed
mice mice
fed fed
anthe
n-6
PUFA
#p<0.05 versus mice of the same exposure group fed an n-6 PUFA diet.
diet. Data were normalized to the housekeeping gene, Hprt. Data are presented
as mean ± SE (n=5-6) and were analyzed by Two-Way ANOVA with Holm-Sidak
post hoc comparisons. *p<0.05 versus air-exposed mice fed the same diet,
#p<0.05 versus mice of the same exposure group fed an n-6 PUFA diet.
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4.4. SHS Increased Left Ventricle + Septum-To-Body Weight Ratio and LungTo-Body Weight Ratio SHS-Exposed Mice Fed a Chow Diet
Body weights of fat-1 mice were not significantly affected by diet or SHS
exposure (Table 4.2). In addition, total heart-to-body weight, right ventricle-tobody weight, and kidneys-to-body weight ratios were not significantly different
due to diet or SHS exposure. The left ventricle + septum-to-body weight ratio was
significantly larger in SHS-exposed mice fed a standard chow diet, compared to
air-exposed mice fed the same diet as well as SHS-exposed mice fed an n-6
PUFA diet. The lung-to-body weight ratio was increased significantly in SHSexposed mice fed a standard chow diet, compared to air-exposed mice also fed a
standard chow diet. Both air- and SHS-exposed mice fed the standard chow diet
had a significantly higher liver-to-body weight ratio, compared to mice fed the n-6
PUFA diet.
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TABLE 4.2. Body and tissue weights of air- and SHS-exposed fat-1 mice fed an
n-6 PUFA or standard chow diet.
n-6 PUFA Diet

Standard Chow Diet

Air

SHS

Air

SHS

Body Weight PreExposure (g)

24.58 ± 0.79

25.38 ± 0.51

25.47 ± 0.26

26.28 ± 0.83

Body Weight PostExposure (g)

28.62 ± 1.03

27.77 ± 0.78

29.46 ± 0.25

27.05 ± 1.47

Total Heart to Body
Weight Ratio (x102)

0.40 ± 0.01

0.40 ± 0.01

0.41 ± 0.01

0.45 ± 0.03

Left Ventricle + Septum
to Body Weight Ratio
(x102)

0.31 ± 0.01

0.31 ± 0.01

0.32 ± 0.01

0.38 ± 0.03*#

Right Ventricle to Body
Weight Ratio (x102)

0.09 ± 0.004

0.08 ± 0.007

0.09 ± 0.004

0.07 ± 0.004

Lung to Body Weight
Ratio (x102)

0.54 ± 0.02

0.55 ± 0.01

0.52 ± 0.01

0.62 ± 0.04*

Liver to Body Weight
Ratio (x102)

4.68 ± 0.08

4.88 ± 0.15

5.35 ± 0.09#

5.99 ± 0.38#

Kidneys to Body Weight
Ratio (x102)

1.01 ± 0.02

0.98 ± 0.02

1.00 ± 0.03

1.10 ± 0.07

aValues

are expressed as mean ± SE (n=6-9). Data were analyzed by Two-Way ANOVA with
Holm-Sidak post hoc comparisons.
*p<0.05 versus air-exposed mice fed the same diet.
#p<0.05 versus mice of the same exposure group fed an n-6 PUFA diet.
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4.5. SHS Exposure Reduced n-3 PUFAs in Mice Fed a Standard Chow Diet, but
Not in Mice Fed an n-6 PUFA Diet
As observed in our previous study, n-3 PUFAs were higher and n-6
PUFAs were lower in mice fed the standard chow diet, compared to mice fed the
n-6 PUFA diet (Table 4.3). Interestingly, however, SHS exposure significantly
reduced the omega-3 index as well as the red blood cell DHA content in mice fed
the standard chow diet, compared to air-exposed mice (Table 4.3, Fig. 4.3A).
However, SHS exposure had no effect on the n-6 PUFA profile of mice fed the
standard chow diet. SHS exposure also had no effect on the red blood cell fatty
acid profile of mice fed the n-6 PUFA diet. Lastly, SHS exposure had no effect on
the n-6/n-3 PUFA ratio (Fig. 4.3B).
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TABLE 4.3. Red blood cell fatty acid composition of fat-1 mice fed an n-6 PUFA
diet or a standard chow diet.
n-6 PUFA Diet
Fatty Acid

Standard Chow Diet

Air

SHS

Air

SHS

C18:3n3
(α-Linolenic, ALA)

0.15 ± 0.01

0.20 ± 0.03

0.49 ± 0.03#

0.57 ± 0.05#

C20:5n3
(Eicosapentaenoic, EPA)

0.85 ± 0.04

0.85 ± 0.05

1.52 ± 0.04#

1.33 ± 0.20#

1.06 ± 0.04

1.01 ± 0.03

1.69 ± 0.05#

1.43 ± 0.18#

5.27 ± 0.13

5.05 ± 0.14

8.11 ± 0.25#

6.48 ± 0.36*#

Omega-3 Index
(EPA+DHA)

6.11 ± 0.16

5.90 ± 0.19

9.63 ± 0.26#

7.81 ± 0.55*#

Σn-3 PUFAs

7.33 ± 0.19

7.11 ± 0.23

11.81 ± 0.28#

9.82 ± 0.75*#

C18:2n6
(Linoleic)

25.02 ± 0.40

25.03 ± 0.49

21.44 ± 0.42#

22.27 ± 0.61#

C18:3n6
(γ-Linolenic)

0.28 ± 0.02

1.69 ± 0.05

0.24 ± 0.01

0.24 ± 0.01

C20:2n6
(Eicosadienoic)

0.43 ± 0.02

0.45 ± 0.03

0.29 ± 0.01#

0.28 ± 0.01#

C20:3n6
(Eicosatrienoic)

1.40 ± 0.03

1.41 ± 0.03

1.69 ± 0.03#

1.62 ± 0.06#

C20:4n6
(Arachidonic)

16.18 ± 0.40

15.82 ± 0.41

10.83 ± 0.41#

9.81 ± 0.88#

C22:4n6
(Docosatetraenoic)

0.99 ± 0.02

0.99 ± 0.02

0.55 ± 0.04#

0.56 ± 0.10#

C22:5n6
(Docosapentaenoic)

0.92 ± 0.04

0.96 ± 0.06

0.31 ± 0.03#

0.33 ± 0.09#

Σn-6 PUFAs

45.23 ± 0.36

44.90 ± 0.34

35.36 ± 0.24#

35.11 ± 0.66#

Σn-6/n-3 PUFA ratio

6.21 ± 0.19

6.37 ± 0.24

3.01 ± 0.08#

3.76 ± 0.49#

n-3 PUFAs

C22:5n3
(Docosapentaenoic,
DPA)
C22:6n3
(Docosahexaenoic,
DHA)

n-6 PUFAs

aValues

are expressed as mean ± SE (n=6-10). Data were analyzed by Two-Way ANOVA with
Holm-Sidak post hoc comparisons.
*p<0.01 versus WT mice fed the same diet.
#p<0.01 versus mice of the same genotype fed an n-6 PUFA diet
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Fig. 4.3. Red blood cell omega-3 Index (A) and n-6/n-3 PUFA ratio (B) air- or
SHS-exposed mice fed an n-6 PUFA diet or a standard chow diet. Data are
presented as mean ± SE (n=6-10) and were analyzed by Two-Way ANOVA with
Holm-Sidak post hoc comparisons. *p<0.01 versus air-exposed mice fed the
same diet, #p<0.01 versus mice of the same exposure group fed an n-6 PUFA
diet.
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4.6. Vasoconstrictor Responses Were Enhanced In SHS-Exposed Fat-1 Mice
Fed an n-6 PUFA Diet
Aortic rings from air- and SHS-exposed mice fed an n-6 PUFA diet or a
standard chow diet were constricted with either PE or U46619 and were
immediately relaxed with either ACh or SNAP.
When dosed with PE, rings from SHS-exposed mice fed an n-6 PUFA diet
had a significantly higher degree of constriction as well as area under the curve
(AUC) than did rings from air-exposed mice fed the same diet (Fig. 4.4A and C).
When rings were treated with PE following L-NNA pre-incubation, a NOS
inhibitor, the rings from SHS-exposed mice fed an n-6 PUFA diet still constricted
significantly more and trended toward a higher AUC than rings from the airexposed mice fed the same diet (Fig. 4.4B and D). There were no differences in
PE constriction or AUC between air- and SHS-exposed mice fed a standard
chow diet (Fig. 4.5A-D).
Similar results were observed when rings were constricted with U46619, a
thromboxane receptor agonist. Aortic rings from SHS-exposed mice fed an n-6
PUFA diet constricted significantly more at the highest dose than did air-exposed
mice fed the same diet. (Fig. 4.6A). When the rings were dosed with U46619
following L-NNA, rings from SHS-exposed mice fed an n-6 PUFA diet constricted
significantly more than air-exposed mice fed the same diet (Fig. 4.6B). Similar to
the results with PE, there were no differences in U46619 constriction between
air- and SHS-exposed mice fed the standard chow diet. significantly between airand SHS-exposed mice fed either diet (Fig. 4.6C and D).
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Regardless of the vasoconstrictor used to pre-constrict the aortic ring,
ACh and SNAP relaxation did not differ between air- and SHS-exposed mice fed
either an n-6 PUFA or standard chow diet (Supplementary Figs. 4.11-4.14).
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Fig. 4.4. PE constriction of aortic rings from air- and SHS-exposed mice fed an
n-6 PUFA diet in the absence (A) and presence (B) of the NOS inhibitor, L-NNA.
PE AUC of aortic rings from air- and SHS-exposed mice fed an n-6 PUFA diet
in the absence (C) and presence (D) of L-NNA. Data are presented as mean ±
SE (n=6-9) and were analyzed by Two-Way RM ANOVA with Holm-Sidak post
hoc comparisons (A,B) or t-test (C,D). *p<0.05 versus air-exposed mice.
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4.7. SHS Exposure Increased Adipose Hmox1 mRNA Expression in Fat-1 Mice
Fed an n-6 PUFA Diet
In order to determine whether oxidative stress is involved in the SHSinduced enhancement of constriction when mice are fed an n-6 PUFA diet,
mRNA expression of Nrf2-regulated antioxidant genes, Hmox1 and Nqo1, were
assessed in adipose, lung, and heart tissue. In adipose, SHS exposure
significantly increased Hmox1 mRNA expression in mice fed an n-6 PUFA diet,
compared to air-exposed mice fed the same diet (Fig. 4.7A). In contrast, there
was no change in Hmox1 mRNA expression in adipose between SHS- and airexposed mice fed the standard chow diet. Additionally, there were no other SHSinduced changes in Hmox1 or Nqo1 mRNA expression observed in adipose,
lung, or heart (Fig. 4.7B-F).

4.8. SHS Exposure Increased Serum Total Antioxidant Capacity in Fat-1 Mice
Fed an n-6 PUFA Diet
Total antioxidant capacity (TAC) was evaluated to further understand the
role of oxidative stress in SHS-induced increases in constriction. SHS exposure
significantly increased TAC in mice fed an n-6 PUFA diet, compared to airexposed mice fed the same diet (Fig. 4.8). Notably, however, SHS had no effect
on TAC in mice fed the standard chow diet.
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Fig. 4.7. mRNA expression of oxidative stress markers, Hmox1 and Nqo1, in
adipose (A,B), lung (C,D), and heart (E,F) tissues from air- and SHS-exposed
mice fed an n-6 PUFA or standard chow diet. Data were normalized to the
housekeeping gene, Hprt. Data are presented as mean ± SE (n=5-6) and were
analyzed by Two-Way ANOVA with Holm-Sidak post hoc comparisons. *p<0.05
versus air-exposed mice fed the same diet, #p<0.05 versus mice of the same
exposure group fed an n-6 PUFA diet.
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Fig. 4.8. Serum
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in fat-1
and SHS-exposed
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4.9. SHS Exposure Did Not Affect Collagen Staining
Cardiac sections (left ventricle) were stained using picro-sirius red to
determine if the 4-week SHS exposure resulted in any fibrosis of the heart.
Collagen staining was found predominantly in a perivascular location and
qualitatively did not appear to differ between mice exposed to SHS or air (Fig.
4.9).
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Fig. 4.9. Picro-sirius red staining of the left ventricle of the heart for fibrosis in
air- and SHS-exposed mice fed an n-6 PUFA diet (A,B) or a standard chow diet
(C,D).
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4.10.

Summary
Constriction to PE and U46619 was enhanced in SHS-exposed mice fed

the n-6 PUFA diet, compared to air-exposed mice fed the same diet. This SHSinduced enhancement of constriction was not evident in mice fed the standard
chow diet. No differences in aortic vasoreactivity to ACh and SNAP were seen
between air- and SHS-exposed mice fed either diet. TAC was increased in SHSexposed mice fed the n-6 PUFA diet compared to air-exposed mice fed the same
diet. Additionally, TAC tended to be higher in chow-fed mice than in n-6 PUFAfed mice. Adipose mRNA expression of the Nrf2-regulated antioxidant enzyme,
Hmox1, was significantly higher in SHS-exposed mice fed an n-6 PUFA diet,
compared to air-exposed mice fed the same diet and SHS-exposed mice fed the
standard chow diet. Lastly, qualitatively, collagen staining of cardiac sections did
not differ between air- and SHS-exposed mice.
Taken together, these data suggest that SHS exposure of mice enhances
vascular constriction and induces indices of an antioxidant response, compared
to air-exposed controls, at an omega-3 index in the intermediate risk range (46%; fat-1 mice on n-6 PUFA diet omega-3 index of 5.9-6.1%). In contrast, when
the omega-3 index is high (9.3 ± 0.3%) and in the range considered protective of
CVD in humans (≥ 8%), SHS exposure of mice significantly reduces omega-3
index by nearly 2% (7.8 ± 0.6). Nonetheless, these levels remain sufficiently high
to prevent the enhancement in vasoconstriction and induction of antioxidant
responses observed when the omega-3 index levels are in the intermediate risk
range (4-8%).
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4.11.

Supplementary Information
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Supplementary Fig. 4.10. Cyp1a1 and Cyp1b1 mRNA expression in lung (A,B)
and heart (C,D) tissues from air- and SHS-exposed mice fed an n-6 PUFA diet
or standard chow diet. Data were normalized to the housekeeping gene, Hprt.
Data are presented as mean ± SE (n=5-6) and were analyzed by Two-Way
ANOVA with Holm-Sidak post hoc comparisons. *p<0.05 versus air-exposed
mice fed the same diet, #p<0.05 versus mice of the same exposure group fed
an n-6 PUFA diet.
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Supplementary Fig. 4.11. ACh relaxation of aortic rings pre-constricted with
PE from air- and SHS-exposed mice fed an n-6 PUFA diet or standard chow
diet in the absence (A,B) and presence (C,D) of L-NNA. Data are presented as
mean ± SE (n=6-9) and were analyzed by Two-Way RM ANOVA with HolmSidak post hoc comparisons (A,B). *p<0.05 versus air-exposed mice fed the
same diet.
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Supplementary Fig. 4.12. ACh relaxation of aortic rings pre-constricted with
U46619 from air- and SHS-exposed mice fed an n-6 PUFA diet or standard
chow diet in the absence (A,B) and presence (C,D) of L-NNA. Data are
presented as mean ± SE (n=6-9) and were analyzed by Two-Way RM ANOVA
with Holm-Sidak post hoc comparisons (A,B). *p<0.05 versus air-exposed mice
fed the same diet.
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Supplementary Fig. 4.13. SNAP relaxation of aortic rings pre-constricted with
PE from air- and SHS-exposed mice fed an n-6 PUFA diet (A) or standard chow
diet (B). Data are presented as mean ± SE (n=6-9) and were analyzed by TwoWay RM ANOVA with Holm-Sidak post hoc comparisons (A,B). *p<0.05 versus
air-exposed mice fed the same diet.
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Supplementary Fig. 4.14. SNAP relaxation of aortic rings pre-constricted with
U46619 from air- and SHS-exposed mice fed an n-6 PUFA diet (A) or standard
chow diet (B). Data are presented as mean ± SE (n=6-9) and were analyzed by
Two-Way RM ANOVA with Holm-Sidak post hoc comparisons (A,B). *p<0.05
versus air-exposed mice fed the same diet.
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CHAPTER 5 - DISCUSSION
5.1. The Role of Omega-3 Polyunsaturated Fatty Acids in Blood Pressure
Regulation
Evidence suggests that n-3 PUFAs are efficacious in reducing blood
pressure in both hypertensive and normotensive individuals (Campbell et al.,
2012; Yang et al., 2016; Filipovic et al., 2018; Yang et al., 2019). However, there
have been few mechanistic studies examining the hypotensive effects of n-3
PUFAs. n-3 PUFA metabolites, activation of voltage-gated potassium channels,
and increases in total antioxidant status and NO bioavailabilty have been
implicated as possible mechanisms (Jayasooriya et al., 2007; Hoshi et al., 2013;
Zhou et al., 2017). In this study, we found that, when fed an n-6 PUFA diet, fat-1
mice have lower MAP, compared to WT, and that this difference in blood
pressure is driven by reductions in DBP.
Previous studies suggest that increased NO bioavailability is an important
mechanism through which n-3 PUFAs are cardioprotective (Takahasi et al.,
2013; Stebbins et al., 2008; Omura et al., 2001; Singh et al., 2010; Wu et al.,
2012; López et al., 2001; López et al., 2004). However, in contrast to previous
studies, we saw no differences in aortic vasoconstriction to PE and only a very
small increase in ACh relaxationat the highest n-3 PUFA levels, suggesting that
neither basal NO, nor stimulated NO, is meaningfully increased in fat-1 mice,
compared to WT mice.
Aside from NO, another major contributor to the regulation of basal blood
pressure is Ang II. To investigate the contribution of Ang II to basal blood
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pressure regulation in WT and fat-1 mice, we treated WT and fat-1 mice with
captopril, an ACE inhibitor, for a period of 3 days and monitored blood pressure
via radiotelemeter. The degree to which blood pressure is reduced under
captopril treatment (Δ) is attributable to the contribution of Ang II to basal blood
pressure regulation. In addition, evidence suggests that treatment with captopril
unmasks the contibution of NO to blood pressure regulation (Bernátová et al.,
1996; Bernátová et al., 1999; Török et al., 2002; Sanchez-Mendoza et al., 1998;
Minami et al., 1995; Pechanova et al., 2006; Sládková et al., 2007). Therefore,
we expected ΔMAP to be equal in WT and fat-1 mice due to equal contributions
of NO to blood pressure regulation as was established in our aortic vasoreactivity
studies. However, when mice were fed the n-6 PUFA diet, there was a trend
towards a significantly larger ΔMAP in fat-1 mice compared to WT. Furthermore,
ΔDBP was significantly higher in fat-1 mice compared to WT. These data did not
support our hypothesis and suggested that, when fed the n-6 PUFA diet, fat-1
mice actually have a greater contribution of Ang II to blood pressure regulation
than do WT mice despite the fact that the MAP of fat-1 mice is significantly lower
than WT at baseline. This conclusion is was not supported by Agt mRNA
expression in adipose, a site of significant AGT production (Pahlavani et al.,
2017), which trended towards a significant decrease (p=0.06) in fat-1 mice,
compared to WT mice fed an n-6 PUFA diet. However, Agt mRNA expression is
a limited assessment of the contribution of Ang II to blood pressure regulation.
Therefore, additional alalyses investigating the involvement of the RAS pathway
must be performed.
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The lower MAP seen in fat-1 mice, compared to WT under basal
conditions, is predominantly driven by reductions in DBP as opposed to SBP as
was evidenced by lower DBP at baseline and higher ΔDBP under captopril
treatment in fat-1 mice, relative to WT mice when fed an n-6 PUFA diet.
Additionally, we saw no changes in heart rate or pulse pressure, which are both
reflective of SBP, once again suggesting that the lower MAP in fat-1 mice on an
n-6 PUFA diet is driven by DBP as opposed to SBP. DBP is largely a product of
peripheral vascular resistance (PVR), so a reduction in DBP in fat-1 mice, but not
in WT mice, is suggestive that fat-1 mice have a lower PVR than do WT mice
when fed an n-6 PUFA diet. A larger ΔDBP under ACE inhibition by captopril in
fat-1 mice compared to WT suggests that removing Ang II reflects a bigger drop
in PVR in fat-1 mice than WT when fed the n-6 PUFA diet. Therefore, Ang II
appears to contribute more to basal DBP and PVR in fat-1 mice than in WT mice
when fed the n-6 PUFA diet.
The fact that MAP at baseline is significanly lower in fat-1 mice than in WT
mice fed an n-6 PUFA diet, despite a greater contribution of Ang II, implies a
contribution of another vasodilator mechanism other than NO. The lower blood
pressure seen in fat-1 mice at baseline could potentially be mediated by
increases in bradykinin, a vasodilator peptide. Bradykinin has previously been
established as playing a key role in the cardioprotective effects of ACE inhibition
such as with captopril. However, previous studies have also suggested that
kinins, including bradykinin, are not essential for the maintenance of basal blood
pressure (Rhaleb et al, 1998). Furthermore, evidence suggests that ACE
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inhibition by captopril does not increase circulating plasma bradykinin levels
(Matthews et al., 1979, MacGregor et al, 1981). As a consequence, bradykinin is
likely not responsible in total for the lower MAP and DBP seen in fat-1 mice,
compared to WT fed an n-6 PUFA diet under basal conditions.
Epoxide metabolites of EPA and DHA (EEQs and EDPs, respectively)
may serve as another mechanism through which MAP and DBP are reduced in
fat-1 mice, compared to their WT littermates. EEQs and EDPs are potent
vasodilators generated from metabolism of EPA and DHA by CYP2C and 2J
(Zhang et al., 2001; Ye et al., 2001; Morin et al. 2008). Epoxide metabolites of n3 PUFAs have been shown to be efficacious in lowering blood pressure. It is
possible that, due to their ability to endogenously convert dietary n-6 PUFAs to n3 PUFAs, fat-1 mice may maintain higher plasma levels of the vasodilatory n-3
PUFA epoxide metabolites than do WT mice. To assess this possibility, an
analysis of plasma and/or tissue fatty acid metabolites would need to be
performed.
Using the fat-1 mouse model as well as its WT littermates, we fed mice an
n-6 PUFA diet and a standard chow diet to produce ranges of omega-3 index
that are similar to that of individuals living in New Mexico (3.88 ± 0.15%) and in
coastal regions such as in Alaskan Eskimos, who have a range of omega-3 index
from 7.01 to 11.63% (Zehr et al., 2019; O’Brien et al., 2009; Parkinson et al.,
1994; Ebbesson et al., 2010; Makhoul et al., 2011). However, the use of the
omega-3 index as a biomarker of n-3 PUFA consumption may be artificial in that,
by definition, the omega-3 index only accounts for red blood cell content of EPA
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and DHA, the long-chain, marine-derived n-3 PUFAs. However, we found that
the red blood cell content of ALA, a shorter-chain, plant-derived n-3 PUFA, is
significantly increased in fat-1 mice, compared to WT, when mice are fed an n-6
PUFA diet. Therefore, it is possible that the reductions seen in MAP and DBP in
fat-1 mice compared to WT when fed an n-6 PUFA diet could be attributable, at
least in part, to ALA.
Many studies have found a similar hypotensive effect of ALA as has been
seen with EPA and DHA. Most notably, a meta-analysis of 11 studies
investigating the efficacy of flaxseed oil to lower blood pressure found reductions
of -1.77 mmHg SBP and -1.58 mmHg DBP (Khalesi et al., 2015). Additionally,
hypertensive individuals taking flaxseed oil supplements (630 mg four times per
day for a total of 90 days) saw significant reductions in MAP, SBP, and DBP
(Yang et al., 2019).
Moreover, in our fat-1 mice, n-6 PUFAs are endogenously converted to n3 PUFAs, so while n-3 PUFA levels increase, n-6 PUFAs also decrease. At this
time, we cannot rule out the possibility that the reductions in blood pressure seen
in fat-1 mice fed an n-6 PUFA diet are actually attributable to decreased n-6
PUFA content. Thus, the n-6 PUFA to n-3 PUFA ratio may serve as a better
index of n-3 PUFA consumption. Furthermore, the distribution of n-3 PUFAs may
vary from tissue to tissue in WT and fat-1 mice. For example, DHA accumulates
more heavily in heart tissue than in red blood cells in WT mice fed an n-3 PUFAenriched diet (Agbor et al., 2014). As a consequence, red blood cells may not be
the optimal tissue for the determination of fatty acid profiles.
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The lack of differences in MAP, SBP, and DBP between WT and fat-1
mice fed a standard chow diet both in the absence and presence of captopril
suggests that an omega-3 index of 4.3 ± 0.2% (measured in WT mice) serves as
a threshold in which the blood pressure-reducing potential of n-3 PUFAs is
maximally effective in mice.
An omega-3 index of less than 4%, as was seen in WT mice fed the n-6
PUFA diet (1.1 ± 0.1%), is considered to be of high cardiovascular risk (Harris
and von Schacky, 2004), while an omega-3 index of greater than 8% is
considered cardioprotective. Taken together, these data demonstrate that, as
omega-3 index increases towards a more cardioprotective level, blood pressure
tends to decrease. This decrease in blood pressure is driven by DBP, thereby
suggesting an effect of n-3 PUFAs on PVR.
Our results highlight a large number of future studies that could further
elucidate the underlying mechanism of n-3 PUFAs beneficial BP lowering effects.
Future studies should evaluate the contribution of NO to basal BP directly by
using NOS inhibitors and the potential contribution of n-3 PUFA epoxide
metabolites to basal BP by using sEH inhibitors. Additionally, the apparent
increased activation of the renin-angiotensin system should be confirmed by
assessing plasma AGT levels and plasma renin activity, the rate limiting
substrate and enzyme in Ang II formation, respectively.
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5.2. The Role of Omega-3 Polyunsaturated Fatty Acids in SHS-Induced
Vascular Dysfunction
In this study, we established an animal model of SHS exposure using the
fat-1 transgenic mouse fed either an n-6 PUFA-enriched diet or a standard chow
diet, resulting in an omega-3 index ranging from 5.9 to 9.6%. We found that,
when fed the standard chow diet (higher n-3 PUFA content and lower n-6 PUFA
content), fat-1 mice (omega-3 index 7.8 ± 0.6%) are protected from SHS-induced
enhancement of aortic constriction as is seen when mice are fed the n-6 PUFA
diet (omega-3 index 6.1 ± 0.1%). Importantly, our data show that n-3 PUFAs
protect against SHS-induced vascular dysfunction in a manner that is
independent of NO.
Dose-dependent responses of aortic rings to PE revealed a significantly
larger degree of constriction of rings from SHS-exposed mice, compared to rings
from air-exposed controls when mice were fed the n-6 PUFA diet. Notably, mice
fed a standard chow diet were protected from SHS-induced increases in PE
constiction. Regardless of diet, however, when the rings were treated with LNNA, a NOS inhibitor, prior to PE, the enhancement of constriction by PE
remained evident in SHS-exposed mice, suggesting that it did not result from a
loss of NO. Dose-dependent constriction of aortic rings with U46619 yielded
similar results. Taken together, this suggested that there was no difference in
basal NO levels in SHS-exposed mice, compared to air-exposed mice,
regardless of diet. Therefore, the differences in PE and U46619 constriction in
mice fed an n-6 PUFA diet likely occurred independent of SHS-induced changes
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in NO bioavailability, which is in contrast to previous reports that SHS exposure
depletes NO (Förstermann and Münzel, 2006; Karbach et al., 2014, Zanetti et al.,
2015).
Moreover, dose-dependent relaxation of aortic rings to ACh was not
reduced by SHS exposure regardless of diet. In the presence of L-NNA,
relaxation was completely inhibited across all groups with no significant
differences between SHS- and air-exposed mice. This implies that SHSexposure does not affect the ability of ACh to stimulate NO production. When
aortic rings were treated with SNAP, an NO donor, relaxation was not impaired
by SHS exposure regardless of diet, thereby indicating that there was also no
effect of SHS in NO signaling downstream of NO generation. Taken together, the
normal NO-dependent relaxation responses and enhanced PE and U46619
constriction, even in the absence of NO, suggest that the vascular effects of SHS
occur independent of changes in NO.
One of the potential mechanisms through which SHS causes vascular
dysfunction is through increases in oxidative stress. Several previous studies
have reported associations between SHS exposure and indices of oxidative
stress. For instance, a study of youth and adolescents found an inverse
correlation between the number of smokers in the home and total antioxidant
capacity (TAC), suggesting that SHS may lower TAC, perhaps through increases
in oxidative stress (Groner et al., 2016). Similarly, another study reported that
SHS-exposed infants and their mothers have a significantly lower TAC than
nonsmoking infants and mothers (Aycicek et al., 2005). In addition, previous
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studies have demonstrated robust increases in the mRNA and protein expression
of Hmox1, an Nrf2-regulated antioxidant genes (Chang et al., 2017; Wiest et al.,
2017). Therefore, we evaluated TAC and measured gene expression of Nrf2regulated antioxidant genes, Hmox1 and Nqo1, in air- and SHS-exposed mice
fed the n-6 PUFA diet or the standard chow diet. In contrast to previous studies,
TAC was increased in SHS-exposed mice fed the n-6 PUFA diet, compared to
air-exposed mice fed the same diet. However, this suggests that SHS is inducing
an antioxidant response, but that the exposure is likely not severe and/or chronic
enough to completely deplete the antioxidant status. In addition, there was
evidence of an induction of Hmox1 mRNA expression in adipose, indicating an
Nrf2-dependent antioxidant response to SHS, which has been seen in previous
studies. Both of these factors suggest the formation of systemic oxidative stress
with SHS exposure when mice were fed the n-6 PUFA diet.
A limited number of animal studies have suggested that SHS exposure
may lead to fibrosis of the heart. For instance, in a Wistar rat model of chronic
SHS exposure (6 months), fibrosis of the heart was evident by picro-sirius red
staining for collagen, compared to unexposed controls (Boor et al., 2010).
Therefore, we assessed the degree of cardiac fibrosis in air-and SHS-exposed
mice fed the n-6 PUFA diet or standard chow diet. Qualitatively, collagen staining
of cardiac sections demonstrated no evidence of fibrosis as a result of SHS
exposure within the left ventricle of the heart. This finding was in contrast to
previous studies suggesting that SHS exposure causes cardiac fibrosis.
However, for such changes to be evident, a more chronic SHS exposure,
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consisting of higher TPM concentrations and a longer duration of exposure, may
be necessary. In addition, a more systematic and blinded quantitative approach
must be delevoped in order to assess for fibrosis of the heart.
In this study, we found that, when fed a standard chow diet, the omega-3
index of SHS-exposed mice (7.8 ± 0.6%) is significantly lower than that of airexposed mice (9.3 ± 0.3%). This finding is in accordance with studies on
mainstream smoke exposure, which have found that smokers have a lower
omega-3 index than nonsmokers (Wiest et al., 2015; Zehr et al., 2019).
In conclusion, we show that mice fed a standard chow diet are protected
from SHS-induced increases in vascular constriction and that this protection
appears to be independent of changes in NO. Further, our data suggest that
there may be a role for systemic oxidative stress in the perpetuation of SHSinduced vascular dysfunction.
Future studies should further evaluate the degree of SHS-induced
oxidative stress systemically and in vascular tissues and whether it contributes to
the enhancement of vasoconstriction using antioxidant therapies such as Nacetyl cysteine. Additionally, studies could be conducted to determine whether
the antioxidant properties of keto-metabolites of n-3 PUFAs contribute to the
mechanism underlying the vasoprotective effect of n-3 PUFAs following SHS
exposure.
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CHAPTER 6 – GLOBAL IMPACT

Hypertension is one of the most common health conditions worldwide and
often precedes clinical CVD (Kearney et al., 2005; Kung et al., 2015). Further,
clinical trials show that reducing blood pressure reduces the risk of myocardial
infarction by 20% - 25%, of stroke by 35%-40%, and of heart failure by 50%
(Antonakoudis et al., 2007). As noted in the Introduction to this thesis, numerous
interventional and observational studies show that n-3 PUFAs reduce blood
pressure in both hypertensive and normotensive individuals. Our animal data are
consistent with these human studies and demonstrate that blood pressure in
normotensive mice is significantly lower when the omega-3 index is above 6%,
compared to an omega-3 index of 1%.
These data are particularly relevant to individuals living in New Mexico.
Our earlier research demonstrated that the omega-3 index in adults in New
Mexico ranges from 1.8-7.4% and is inversely associated with both SBP and
DBP (Zehr et al., 2019). Thus, our experimental animal data (1) establish a
cause-and-effect relationship between the omega-3 index and BP lowering and
(2) demonstrate this relationship over the same range of omega-3 indices
measured in New Mexicans. This provides evidence supporting the concept that
increased dietary n-3 PUFAs can lower BP and thus have the potential reduce
CVD risk. Additionally, this evidence establishes the use of the fat-1 mouse
model to further investigate the mechanisms through which n-3 PUFAs mediate
their beneficial BP lowering effects.
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While hypertension is one of the most common health conditions, CVD is
the leading cause of death in the United States and it is well established that
SHS exposure increases CVD risk by up to 30% (US Department of Health and
Human Services, 2006). Although recent meta-analyses of randomized clinical
trials suggest that n-3 PUFAs may be of limited benefit in secondary prevention
of CVD, observational studies provide a large body of evidence suggesting that
dietary n-3 PUFAs have protective effects on primary prevention of CVD (Del
Gobbo et al., 2016; Harris et al., 2017; Harris et al., 2018; Alexander et al., 2017;
Pan et al., 2012; Wei et al., 2018; von Schacky, 2011; de Oliveira Otto et al.,
2013) . Therefore, dietary consumption of n-3 PUFAs may represent a novel
means through which the development or severity of CVD may be reduced or
prevented following SHS exposure. Our data showing that higher n-3 PUFAs
protect against SHS-induced vascular dysfunction provide evidence of how
dietary n-3 PUFAs may reduce CVD risk following SHS exposure.
Individuals exposed to SHS are unique from mainstream smokers in that
they smoke involuntarily. In addition, individuals exposed to SHS often make up
a handful of especially at-risk groups, including pregnant women and children.
Smoking cessation and smoke-free legislation are still some of the most powerful
means of preventing SHS exposure, but SHS exposure also occurs at home and
in other private places. Therefore, our research findings could be important in
preventing SHS-induced vascular dysfunction in those who are unable to escape
the reality of living with a smoker or working in a smoky environment, such as a
casino.
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Taken together, our studies provide evidence of a beneficial effect of n-3
PUFAs in reducing blood pressure and preventing SHS-induced vascular
dysfunction, both of which could contribute to lowering CVD risk.
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